🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 14 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/01/2008 37,05 38,18 36,90 37,73 +1,45% 3,45% 2.121.100
03/01/2008 36,79 37,80 36,66 37,19 +1,50% 3,10% 2.983.800
02/01/2008 35,49 36,87 35,22 36,64 +3,50% 4,65% 2.147.200
31/12/2007 35,57 35,80 35,21 35,40 -0,56% 1,66% 791.500
28/12/2007 35,95 36,11 35,33 35,60 -0,95% 2,17% 1.057.900
27/12/2007 36,44 36,73 35,93 35,94 -1,75% 2,20% 1.133.900
26/12/2007 36,43 37,01 36,25 36,58 +0,03% 2,09% 1.244.400
24/12/2007 36,42 37,00 36,16 36,57 +0,72% 2,31% 669.000
21/12/2007 35,73 36,42 35,52 36,31 +2,69% 2,52% 2.772.600
20/12/2007 34,35 35,42 34,02 35,36 +1,99% 4,08% 1.717.600
19/12/2007 34,32 35,35 33,64 34,67 -0,49% 4,98% 2.961.000
18/12/2007 35,11 35,57 33,55 34,84 -0,94% 5,75% 3.270.600
17/12/2007 35,44 36,00 34,97 35,17 -3,49% 2,91% 3.218.800
14/12/2007 35,76 37,17 35,29 36,44 +22,45% 5,26% 17.258.100
13/12/2007 27,89 30,49 26,75 29,76 +5,61% 13,41% 11.975.300
12/12/2007 28,64 29,00 27,87 28,18 -1,74% 3,95% 2.125.000
11/12/2007 28,32 29,09 27,72 28,68 +1,45% 4,84% 2.047.500
10/12/2007 28,02 28,58 27,76 28,27 +1,00% 2,93% 1.526.800
07/12/2007 28,90 29,16 27,73 27,99 -2,74% 4,95% 1.468.500
06/12/2007 26,84 28,85 26,81 28,78 +6,83% 7,60% 2.163.800
05/12/2007 26,92 27,23 26,75 26,94 +1,51% 1,78% 2.020.600
04/12/2007 27,25 27,45 26,41 26,54 -2,96% 3,82% 1.552.500
03/12/2007 27,67 27,75 27,22 27,35 -0,55% 1,92% 1.095.900
30/11/2007 28,11 28,41 27,29 27,50 -0,58% 3,98% 897.700
29/11/2007 26,81 28,08 26,76 27,66 +2,94% 4,92% 787.200
28/11/2007 26,66 27,19 26,22 26,87 +2,25% 3,64% 1.054.500
27/11/2007 25,54 26,31 25,35 26,28 +2,86% 3,76% 884.100
26/11/2007 26,24 26,48 25,50 25,55 -2,56% 3,73% 909.800
23/11/2007 25,78 26,32 25,75 26,22 +2,58% 2,21% 307.400
21/11/2007 25,98 26,25 25,17 25,56 -2,18% 4,16% 1.429.400